Indeed, high expression of MAF is associated with innate resistance to proteasome inhibitor treatment [276,277,278] and silencing MAF sensitized MM cells to proteasome inhibitors, while proteasome inhibition abrogated GSK3β-mediated degradation of c-MAF, effectively stabilizing MAF activity [276,278]. The gene discussed is MAF; the disease is Miyoshi myopathy.